ACCEL-HYOSCINE DIN 02512335
Health Canada record
| Active ingredient(s) | HYOSCINE BUTYLBROMIDE 10 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | ETHICAL |
| Class | Human |
| ATC | A03BB01 BUTYLSCOPOLAMINE |
| Original market date | 19-Aug-2021 |
| Current status date | 19-Aug-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Accel Pharma Inc — licence 101722, currently licensed, last inspection rating C (2025-07-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing HYOSCINE BUTYLBROMIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00363812 | BUSCOPAN | SANOFI CONSUMER HEALTH INC | Tablet | HYOSCINE BUTYLBROMIDE 10 MG | Marketed |
| 00363839 | BUSCOPAN | SANOFI CONSUMER HEALTH INC | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Marketed |
| 02282089 | BUSCOPAN INJECTION FOR HORSES | BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Marketed |
| 02229868 | HYOSCINE BUTYLBROMIDE INJECTION | SANDOZ CANADA INCORPORATED | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Marketed |
| 02560984 | HYOSCINE BUTYLBROMIDE INJECTION | AS KALCEKS | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Approved |
| 02508419 | HYOSCINE BUTYLBROMIDE INJECTION BP | OMEGA LABORATORIES LIMITED | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Marketed |
| 00363820 | BUSCOPAN SUP 10MG | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Suppository | HYOSCINE BUTYLBROMIDE 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25208 | 2021-02-12 | Abbreviated New Drug Submission (ANDS) |
International API supply for HYOSCINE BUTYLBROMIDE
7 valid EDQM Certificates of Suitability from 7 holders.
Request a quote for ACCEL-HYOSCINE